A multicenter randomized phase III trial of nonpegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide (MC) versus liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line treatment in locally advanced (LABC) or metastatic breast cancer (MBC).
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2014
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Vinorelbine; Vinorelbine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 16 Jun 2011 New trial record
- 07 Jun 2011 Interim results (n=228) presented at the 47th Annual Meeting of the American Society of Clinical Oncology.